

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addease COMMISSIONER FOR PATENTS PO Box 1430 Alexandra, Virginia 22313-1450 www.webjo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/782,554	02/19/2004	Brooke L. Small	210507US (4081-03900)	5152	
37814 7590 10/23/2008 EXAN				MINER	
5601 Granite Parkway, Suite 750			NGUYEN, TAM M		
PLANO, TX 7	5024		ART UNIT	PAPER NUMBER	
			1797		
			MAIL DATE	DELIVERY MODE	
			10/23/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/782,554	SMALL ET AL.		
Examiner	Art Unit		
TAM M. NGUYEN	1797		

The MAILING DATE of this communication appears on the cover sheet with the correspondence address
THE REPLY FILED 07 October 2008 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.
1. Me reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 3 To ATI, 1; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time
periods:
a) The period for reply expiresmonths from the mailing date of the final rejection.
b) \(\times \) The period for reply expires on: (1) the mailling date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailling date of the final rejection.
Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).
Extensions of time may be obtained under 37 CFR 1,136(a). The date on which the petition under 37 CFR 1,136(a) and the appropriate extension fee have been filled is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1,17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (a) above, if checked. Any reply received by the Office late it has three months after the mailing date of the final rejection, even if timely filled, may reduce any semed patent term adjustment. See 37 CFR 1,704(b). NOTICE OF APPEAL
2. The Notice of Appeal was filed on A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of
filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).
AMENDMENTS
3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below); (b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to blace the application in better form for appeal by materially reducing or simplifying the issues for
appeal; and/or
(d) ☐ They present additional claims without canceling a corresponding number of finally rejected claims.
NOTE: New added claims 77 and 78 raise new issues that would require further consideration and/or search. Therefore, the amendment will not be entered. (See 37 CFR 1.116 and 41.33(a)).
4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).
5. Applicant's reply has overcome the following rejection(s):
6. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the
non-allowable claim(s).
7. For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The claims of the claims of the claims (a) is (a) will be a follower.

Claim(s) allowed: Claim(s) objected to:

Claim(s) rejected: 1-12,20-29,31-38,46-54 and 56-67

Claim(s) withdrawn from consideration: _____.

AFFIDAVIT OR OTHER EVIDENCE

8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).

9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).

10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

REQUEST FOR RECONSIDERATION/OTHER

11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.

2.	Note the	attached	Information	Disclosure	Statement(s).	(PTO/SB/08)	Paper No(s)	

13. Other: ___

/Tam M. Nguyen/ Primary Examiner, Art Unit 1797 Continuation of 11, does NOT place the application in condition for allowance because: The argument that DeBoer does not teach a diluent comprising 1-butnen, 1-dodecene, 1-terdadecene, 1-hexadecene, 1-octadecene or combination thereof is not persuasive. DeBoer teaches that the product stream from the oligomerization reactor comprises 1-dodecene as claimed. The limitation "diluent" is encompassed by DeBoer. It is reminded that appliant just names 1-dodecene as a diluent.

The argument that a significant distinction between the present invention and the the process of DeBoer is that the presently claims recite reactive diluents in contrast to inert solvents used by DeBoer is not persuasive. As discussed above, Deboer beaches that the product stream from the oligomerization reactor comprises 1-dodecene as claimed. Since 1-dodecene is the same as the claimed diluent, it would be expected that 1-dodecene would has a function as discussed. There is no distintion between the claimed 1-dodecene diluent and 1-dodecene of DeBore. The claimed process does not exclude a use of an inert sovent and also does not recite that the diluent is a reactive diluent.

The argument that one of ordinary skill in the art would readily appreciate the different between a 1-dodecene diluent as recited in the pending claims and DeBoer's 1-dodecene reaction product is not persuasive. The pending claims recite that the effluent from the reaction zone comprising a diluent such as 1-dodecene, DeBore teaches that the effluent from the reaction zone comprising 1-dodecene of claims of There is no distintion between the claimed 1-dodecene of 1-dodecene of DeBore.